HealthProves
Home/injectables/tretinoin
REPORTED SIGNALS

tretinoin

Retin-A · Atralin · Renova

Registration status unknownDruginjectablesMajor Pharmaceuticals
ORAL

1 INDICATIONS AND USAGE Tretinoin capsules are indicated for the induction of remission in adults and pediatric patients 1 year of age and older with acute promyelocytic leukemia (APL) characterized by the presence of the t(15;17) translocation or PML/RARα gene expression, and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-based chemotherapy is contraindicated. Tretinoin capsules are a retinoid indicated for induction of remission in adults and pediatric patients 1 year of age and older with acute promyelocytic leukemia (APL), characterized by presence of t(15;17) translocation or presence of PML/RARα gene expression, and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-based chemotherapy is contraindicated.

Mechanism. 12.1 Mechanism of Action Tretinoin induces cytodifferentiation and decreased proliferation of APL cells in culture and in vivo . In APL patients, tretinoin treatment produces an initial maturation of the primitive promyelocytes derived from the leukemic clone, followed by a repopulation of the bone marrow and peripheral blood by normal, polyclonal hematopoietic cells in patients achieving complete remission (CR). The exact mechanism of action of tretinoin in APL is unknown.

FDA BOXED WARNING

FDA requires a boxed warning on this label. See full prescribing information.

Read full label →
8,579
reports (FAERS)
56.0%
reported as serious
637
fatal reports (7.4%)
30
signals above threshold
1974
first approved
2026-07
last updated
TIMELINE · FDA MILESTONES
Approved
1974
1973
2026
SIGNAL RANKING · ROR

What stands out in the reports.

On the labelNew signalUnknown & frequent
Symptom
0.1110100
ROR [95% CI]
Differentiation Syndrome
1156.0 [981.71361.2]
Blepharospasm
120.5 [106.6136.3]
Taste Disorder
39.4 [35.144.2]
Epilepsy
24.0 [21.327.0]
Gastrooesophageal Reflux Disease
10.2 [9.111.4]
Maternal Exposure During Pregnancy
8.9 [7.910.0]
Blister
8.8 [7.710.2]
DRUG Intolerance
8.7 [7.89.7]
SKIN Exfoliation
7.9 [7.08.9]
Migraine
7.5 [6.68.4]
Treatment Failure
6.6 [5.77.5]
ACNE
6.4 [5.67.4]
Intentional Product USE Issue
6.3 [5.57.2]
Paraesthesia
6.2 [5.66.9]
DRY SKIN
6.0 [5.46.7]

ROR = reporting odds ratio (log scale). A value above 1 means the symptom is reported more often for this product than for all other products combined. This measures how much it stands out in reports — not cause, not risk.

INTERPRETATION
Auto-generated

Tretinoin shows disproportionately reported adverse effects like maternal exposure during pregnancy, blisters, and skin exfoliation. Maternal exposure is logical as tretinoin is known to harm unborn babies. Blisters and skin exfoliation are also expected, as tretinoin works by speeding up skin cell turnover. Remember, "frequently reported" does not mean "frequently caused." These signals show what's reported more often than average, not how often tretinoin actually causes them. This does not replace medical advice.

This does not replace medical advice.

LABEL VERSUS REPORT
On the label

No signals currently mapped to the label.

Newly reported
Differentiation Syndrome
Blepharospasm
Taste Disorder
Epilepsy
Gastrooesophageal Reflux Disease
Maternal Exposure During Pregnancy
Blister
DRUG Intolerance
REPORTS OVER TIME

Report volume per quarter.

19741975197619771979
RECALL HISTORY · 0 ON RECORD

No recalls on record.

COMPARE WITHIN INJECTABLES
bimatoprost
Latisse · Lumigan
Reports28,372
Compare with tretinoin
SOURCE & CITATION
HealthProves. tretinoin — reported signals. Retrieved 2026-07-04. Source: openFDA (FAERS). healthproves.com/tretinoin/
FAERS8,579 records
Retrieved2026-07-04
MethodROR / disproportionality